Accès gratuit
Numéro
Réanimation
Volume 24, Numéro 3, Mai 2015
Infectieux
Page(s) 328 - 336
Section Mise Au Point / Update
DOI https://doi.org/10.1007/s13546-015-1067-1
Publié en ligne 10 avril 2015
  • Carlet J, Rambaud C, Pulcini C, on behalf of WAAR, international section of the Alliance Contre le développement des Bactéries Multi-résistantes (AC-de-BMR), (2012) WAAR (World Alliance against Antibiotic Resistance): Safeguarding antibiotics. Antimicrob Resist Infect Control 1:25 [CrossRef] [PubMed] [Google Scholar]
  • Rosenbaum L, Lamas D (2012) Cents and sensitivity–teaching physicians to think about costs. New Engl J Med 367:99–101 [CrossRef] [Google Scholar]
  • Bhat S, Fujitani S, Potoski BA, et al (2007) Pseudomonas aeruginosa infections in the intensive care unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved? Int J Antimicrob Agents 30:458–462 [CrossRef] [PubMed] [Google Scholar]
  • Marcus R, Paul M, Elphick H, Leibovici L (2011) Clinical implications of beta-lactam-aminoglycoside synergism: systematic review of randomised trials. Int J Antimicrob Agents 37:491–503 [CrossRef] [PubMed] [Google Scholar]
  • Duszynska W, Taccone FS, Hurkacz M, et al (2013) Therapeutic drug monitoring of amikacin in septic patients. Crit Care 17:R165 [CrossRef] [PubMed] [Google Scholar]
  • Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L (2004) Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematicreview and meta-analysis of randomised trials. BMJ 328:668 [CrossRef] [PubMed] [Google Scholar]
  • Kumar A, Safdar N, Kethireddy S, Chateau D (2010) A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med 38:1651–1664 [CrossRef] [PubMed] [Google Scholar]
  • Martinez JA, Cobos-Trigueros N, Soriano A, et al (2010) Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother 54:3590–3596 [CrossRef] [PubMed] [Google Scholar]
  • Drusano GL, Louie A (2011) Optimization of aminoglycoside therapy. Antimicrob Agents Chemother 55:2528–2531 [CrossRef] [PubMed] [Google Scholar]
  • Oostdijk EA, Kesecioglu J, Schultz MJ, et al (2014) Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: a randomized clinical trial. JAMA 312:1429–1437 [CrossRef] [PubMed] [Google Scholar]
  • Hirsch EB, Tam VH (2010) Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 65:1119–1125 [CrossRef] [PubMed] [Google Scholar]
  • Park SH, Choi SM, Chang YK, et al (2014) The efficacy of noncarbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother 69:2848–2856 [CrossRef] [PubMed] [Google Scholar]
  • Rea RS, Capitano B (2007) Optimizing use of aminoglycosides in the critically ill. Semin Respir Crit Care Med 28:596–603 [CrossRef] [PubMed] [Google Scholar]
  • Lugo G, Castaneda-Hernandez G (1997) Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med 25:806–811 [CrossRef] [PubMed] [Google Scholar]
  • Botha FJ, van der Bijl P, Seifart HI, Parkin DP (1996) Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient. Intensive Care Med 22:443–446 [CrossRef] [PubMed] [Google Scholar]
  • Barletta JF, Johnson SB, et al (2000) Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. J Trauma 49:869–872 [CrossRef] [PubMed] [Google Scholar]
  • Hickling K, Begg E, Moore ML (1989) A prospective randomised trial comparing individualised pharmacokinetic dosage prediction for aminoglycosides with prediction based on estimated creatinine clearance in critically ill patients. Intens Care Med 15:233–237 [CrossRef] [Google Scholar]
  • Tholl DA, Shikuma LR, Miller TQ, et al (1993) Physiologic response of stress and aminoglycoside clearance in critically ill patients. Crit Care Med 21:248–251 [CrossRef] [PubMed] [Google Scholar]
  • Kashuba AD, Nafziger AN, Drusano GL, et al (1999) Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 43:623–629 [PubMed] [Google Scholar]
  • Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH (1997) Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 39:677–686 [CrossRef] [PubMed] [Google Scholar]
  • Rybak MJ, Abate BJ, Kang SL, et al (1999) Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 43:1549–1555 [PubMed] [Google Scholar]
  • Hajkowicz KM, Post JJ (2011) Does aminoglycoside therapy cause significant acute kidney injury in febrile neutropenia? Int J Antimicrob Agents 37:78–81 [CrossRef] [PubMed] [Google Scholar]
  • Boyer A, Gruson D, Bouchet S, et al (2013) Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk. Drug safety 36:217–230 [CrossRef] [PubMed] [Google Scholar]
  • Boucher BA, Coffey BC, Kuhl DA, et al (1990) Algorithm for assessing renal dysfunction risk in critically ill trauma patients receiving aminoglycosides. Am J Surg 160:473–480 [CrossRef] [PubMed] [Google Scholar]
  • Picard W, Bazin F, Clouzeau B, et al (2014) Propensity-based study of aminoglycoside nephrotoxicity in patients with severe sepsis or septic shock. Antimicrob Agents Chemother 58:7468–7474 [CrossRef] [PubMed] [Google Scholar]
  • Barza M, Ioannidis JP, Cappelleri JC, Lau J (1996) Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 312:338–345 [CrossRef] [PubMed] [Google Scholar]
  • Buchholtz K, Larsen CT, Hassager C, Bruun NE (2009) Severity of gentamicin’s nephrotoxic effect on patients with infective endocarditis: a prospective observational cohort study of 373 patients. Clin Infect Dis 48:65–71 [CrossRef] [PubMed] [Google Scholar]
  • Mavros MN, Polyzos KA, Rafailidis PI, Falagas ME (2011) Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and meta-analysis. J Antimicrob Chemother 66:251–259 [CrossRef] [PubMed] [Google Scholar]
  • Matzke GR, Frye RF (1997) Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. Drug safety 16:205–231 [CrossRef] [PubMed] [Google Scholar]
  • Rougier F, Claude D, Maurin M, et al (2003) Aminoglycoside Nephrotoxicity: Modeling, Simulation, and Control. Antimicrob Agents Chemother 47:1010–1016 [CrossRef] [PubMed] [Google Scholar]
  • Lopez-Novoa JM, Quiros Y, Vicente L, et al (2011) New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 79:33–45 [CrossRef] [PubMed] [Google Scholar]
  • Bartal C, Danon A, Schlaeffer F, et al (2003) Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med 114:194–198 [CrossRef] [PubMed] [Google Scholar]
  • Kirkpatrick CM, Duffull SB, Begg EJ, Frampton C (2003) The use of a change in gentamicin clearance as an early predictor of gentamicin-induced nephrotoxicity. Ther Drug Monit 25:623–630 [CrossRef] [PubMed] [Google Scholar]
  • Olsen KM, Rudis MI, Rebuck JA, et al (2004) Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med 32:1678–1682 [CrossRef] [PubMed] [Google Scholar]
  • Kirkpatrick CM, Duffull SB, Begg EJ (1997) Once-daily aminoglycoside therapy: potential ototoxicity. Antimicrob Agents Chemother 41:879–880 [PubMed] [Google Scholar]
  • Verdel BM, van Puijenbroek EP, Souverein PC, et al (2008) Drug-related nephrotoxic and ototoxic reactions: a link through a predictive mechanistic commonality. Drug safety 31:877–888 [CrossRef] [PubMed] [Google Scholar]
  • Feldman L, Efrati S, Eviatar E, et al (2007) Gentamicininduced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int 72:359–363 [CrossRef] [PubMed] [Google Scholar]
  • Beaucaire G (2000) Does once-daily dosing prevent nephrotoxicity in all aminoglycosides equally? Clin Microbiol Infect 6:357–362 [CrossRef] [PubMed] [Google Scholar]
  • Matthaiou DK, De Waele J, Dimopoulos G (2014) What is new in the use of aminoglycosides in critically ill patients? Intensive Care Med 40:1553–1555 [CrossRef] [PubMed] [Google Scholar]
  • Radigan EA, Gilchrist NA, Miller MA (2010) Management of aminoglycosides in the intensive care unit. J Intensive Care Med 25:327–342 [CrossRef] [PubMed] [Google Scholar]
  • Zahar JR, Rioux C, Girou E, et al (2006) Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team. J Antimicrob Chemother 58:651–656 [CrossRef] [PubMed] [Google Scholar]
  • Tod M, Minozzi C, Beaucaire G, et al (1999) Isepamicin in intensive care unit patients with nosocomial pneumonia: population pharmacokinetic-pharmacodynamic study. J Antimicrob Chemother 44:99–108 [CrossRef] [PubMed] [Google Scholar]
  • 2011) Mise au point sur le bon usage des aminosides administrés par voie injectable: gentamicine, tobramycine, nétilmicine, amikacine. Wwwafssapsfr [Google Scholar]
  • Potel GCJ, Jacqueline C, Navas D, et al (2006) Antibiotic dosages in intensive care unit: when and how should we ask for and perform tests? Reanimation 15:187–192 [CrossRef] [Google Scholar]
  • Taccone FS, Laterre PF, Spapen H, et al (2010) Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 14:R53 [CrossRef] [PubMed] [Google Scholar]
  • De Montmollin E, Bouadma L, Gault N, et al (2014) Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Med 40:998–1005 [CrossRef] [PubMed] [Google Scholar]
  • Nicolau DP, Freeman CD, Belliveau PP, et al (1995) Experience with a once-daily aminoglycoside program administered to 2, 184 adult patients. Antimicrob Agents Chemother 39:650–655 [CrossRef] [PubMed] [Google Scholar]
  • Pieracci FM, Barie PS, Pomp A (2006) Critical care of the bariatric patient. Crit Care Med 34:1796–1804 [CrossRef] [PubMed] [Google Scholar]
  • Pai MP, Nafziger AN, Bertino JSJr (2011) Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother 55:4006–4011 [CrossRef] [PubMed] [Google Scholar]
  • Cartin-Ceba R, Haugen EN, Iscimen R, et al (2009) Evaluation of “loss” and “end stage renal disease” after acute kidney injury defined by the Risk, Injury, Failure, Loss and ESRD classification in critically ill patients. Intensive Care Med 35:2087–2095 [CrossRef] [PubMed] [Google Scholar]
  • Sowinski KM, Magner SJ, Lucksiri A, et al (2008) Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol 3:355–361 [CrossRef] [PubMed] [Google Scholar]
  • Aronoff GR BW, Berns JS, Brier ME, et al (2007) Drug precsribing in renal failure: dosing guidelines for adults and children. Philadelphia [Google Scholar]
  • Matsuo H, Hayashi J, Ono K, et al (1997) Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality. Antimicrob Agents Chemother 41:2597–2601 [PubMed] [Google Scholar]
  • Veinstein A, Venisse N, Badin J, et al (2013) Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered. Antimicrob Agents Chemother 57:977–982 [CrossRef] [PubMed] [Google Scholar]
  • Golper TA (2001) Update on drug sieving coefficients and dosing adjustments during continuous renal replacement therapies. Contrib Nephrol 132:349–353 [CrossRef] [PubMed] [Google Scholar]
  • Trotman RL, Williamson JC, Shoemaker DM, Salzer WL (2005) Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 41:1159–1166 [CrossRef] [PubMed] [Google Scholar]
  • Yamamoto T, Yasuno N, Katada S, et al (2011) Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration. Antimicrobial Agents Chemother 55:5804–5812 [CrossRef] [Google Scholar]
  • Roberts JA, Field J, Visser A, et al (2010) Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. Antimicrob Agents Chemother 54:3635–3640 [CrossRef] [PubMed] [Google Scholar]
  • Bogard KN, Peterson NT, Plumb TJ, et al (2011) Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients. Crit Care Med 39:560–570 [CrossRef] [PubMed] [Google Scholar]
  • Slaughter RL, Cappelletty DM (1998) Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring. PharmacoEconomics 14:385–394 [CrossRef] [PubMed] [Google Scholar]
  • Tod MM, Padoin C, Petitjean O (2001) Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods? Clin Pharmacokinet 40:803–814 [CrossRef] [PubMed] [Google Scholar]
  • Toschlog EA, Blount KP, Rotondo MF, et al (2003) Clinical predictors of subtherapeutic aminoglycoside levels in trauma patients undergoing once-daily dosing. J Trauma 55:255–260 [CrossRef] [PubMed] [Google Scholar]
  • Buijk SE, Mouton JW, Gyssens IC, et al (2002) Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 28:936–942 [CrossRef] [PubMed] [Google Scholar]
  • Wallace AW, Jones M, Bertino JS (2002) Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy 22:1077–1083 [CrossRef] [PubMed] [Google Scholar]
  • Sawchuk RJ, Zaske DE (1976) Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm 4:183–195 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.